Home
EXEL
EXEL News

Latest Exelixis Inc. (EXEL) News on June 21, 2025

MT Newswires

a day ago

Exelixis Says Partner Ipsen Gets EU Panel Backing for Cabometyx to Treat Neuroendocrine Tumors

Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Business Wire

a day ago

Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma

Zacks

2 days ago

Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Zacks

2 days ago

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Those who invested in Exelixis (NASDAQ:EXEL) three years ago are up 102%

Simply Wall St.

2 days ago

Those who invested in Exelixis (NASDAQ:EXEL) three years ago are up 102%

Here's Why Exelixis (EXEL) is a Strong Value Stock

Zacks

3 days ago

Here's Why Exelixis (EXEL) is a Strong Value Stock

EXEL or ARGX: Which Is the Better Value Stock Right Now?

Zacks

4 days ago

EXEL or ARGX: Which Is the Better Value Stock Right Now?

Zacks.com featured highlights include Flex, CVS Health, Urban Outfitters and Exelixis

Zacks

8 days ago

Zacks.com featured highlights include Flex, CVS Health, Urban Outfitters and Exelixis

Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report?

Zacks

9 days ago

Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report?

Can ‘reputational pull’ save biotech from pharma’s image problem?

Pharma Voice

9 days ago

Can ‘reputational pull’ save biotech from pharma’s image problem?

3 Underfollowed Stocks on the Move Now (OLO, PLMR, EXEL)

Zacks

10 days ago

3 Underfollowed Stocks on the Move Now (OLO, PLMR, EXEL)

Argus Research

11 days ago

EXEL: What does Argus have to say about EXEL?

3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)

Zacks

12 days ago

3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)

This IBD 50 Biotech's Got 'Rhythm' — And Flashes 3 Telltale Clues

Investor's Business Daily

15 days ago

This IBD 50 Biotech's Got 'Rhythm' — And Flashes 3 Telltale Clues

Kymera Therapeutics Stock Earns 92 RS Rating

Investor's Business Daily

15 days ago

Kymera Therapeutics Stock Earns 92 RS Rating

Are You Looking for a Top Momentum Pick? Why Exelixis (EXEL) is a Great Choice

Zacks

15 days ago

Are You Looking for a Top Momentum Pick? Why Exelixis (EXEL) is a Great Choice

BofA Hikes Exelixis, Inc. (EXEL) Target Amid CRC Caution

Insider Monkey

16 days ago

BofA Hikes Exelixis, Inc. (EXEL) Target Amid CRC Caution

Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell?

Zacks

17 days ago

Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell?

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

Zacks

17 days ago

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

Here's Why Exelixis (EXEL) is a Strong Growth Stock

Zacks

19 days ago

Here's Why Exelixis (EXEL) is a Strong Growth Stock

Top 4 Value Stocks With Impressive PEG Ratios to Buy Now

Zacks

22 days ago

Top 4 Value Stocks With Impressive PEG Ratios to Buy Now

2 Top Stocks to Buy With Less Than $100

Motley Fool

22 days ago

2 Top Stocks to Buy With Less Than $100

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

Zacks

24 days ago

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)

Zacks

a month ago

3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)

Earnings Estimates Moving Higher for Exelixis (EXEL): Time to Buy?

Zacks

a month ago

Earnings Estimates Moving Higher for Exelixis (EXEL): Time to Buy?

Exelixis (EXEL) Upgraded to Buy: What Does It Mean for the Stock?

Zacks

a month ago

Exelixis (EXEL) Upgraded to Buy: What Does It Mean for the Stock?

EXEL vs. ARGX: Which Stock Is the Better Value Option?

Zacks

a month ago

EXEL vs. ARGX: Which Stock Is the Better Value Option?

EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort

Zacks

a month ago

EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort

Solid Earnings Reflect Exelixis' (NASDAQ:EXEL) Strength As A Business

Simply Wall St.

a month ago

Solid Earnings Reflect Exelixis' (NASDAQ:EXEL) Strength As A Business

Product Performance, Big Money Lift Exelixis

FX Empire

a month ago

Product Performance, Big Money Lift Exelixis

MT Newswires

a month ago

Exelixis Insider Sold Shares Worth $1,515,091, According to a Recent SEC Filing

MT Newswires

a month ago

Exelixis Reports 'Encouraging' Data in Kidney Cancer Trial

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025

Business Wire

a month ago

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June

Business Wire

a month ago

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June

Exelixis (NasdaqGS:EXEL) Reports Robust Q1 2025 Earnings and Revenue Growth

Simply Wall St.

a month ago

Exelixis (NasdaqGS:EXEL) Reports Robust Q1 2025 Earnings and Revenue Growth

Argus Research

a month ago

EXEL: Raising target price to $49.00

ACADIA Pharmaceuticals Stock Sees RS Rating Jump To 93

Investor's Business Daily

a month ago

ACADIA Pharmaceuticals Stock Sees RS Rating Jump To 93

Exelixis (EXEL) is a Great Momentum Stock: Should You Buy?

Zacks

a month ago

Exelixis (EXEL) is a Great Momentum Stock: Should You Buy?

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Zacks

a month ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Unlocking Exelixis (EXEL) International Revenues: Trends, Surprises, and Prospects

Zacks

a month ago

Unlocking Exelixis (EXEL) International Revenues: Trends, Surprises, and Prospects

MT Newswires

a month ago

Exelixis Insider Sold Shares Worth $4,600,000, According to a Recent SEC Filing

MT Newswires

a month ago

Exelixis Insider Sold Shares Worth $1,619,130, According to a Recent SEC Filing

MT Newswires

a month ago

Exelixis Insider Sold Shares Worth $1,154,500, According to a Recent SEC Filing

MT Newswires

a month ago

Exelixis Insider Sold Shares Worth $6,488,503, According to a Recent SEC Filing

Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term

Zacks

a month ago

Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term

Company News for May 15, 2025

Zacks

a month ago

Company News for May 15, 2025

Why Exelixis, Inc. (EXEL) Skyrocketed On Wednesday

Insider Monkey

a month ago

Why Exelixis, Inc. (EXEL) Skyrocketed On Wednesday

These Stocks Moved the Most Today: Nvidia, AMD, Super Micro, UnitedHealth, eToro, Oklo, Exelixis, and More

Barrons.com

a month ago

These Stocks Moved the Most Today: Nvidia, AMD, Super Micro, UnitedHealth, eToro, Oklo, Exelixis, and More

eToro's Nasdaq debut, Exelixis outlook, Septerna–Novo deal

Yahoo Finance Video

a month ago

eToro's Nasdaq debut, Exelixis outlook, Septerna–Novo deal

Why Exelixis Stock Is Skyrocketing Today

Motley Fool

a month ago

Why Exelixis Stock Is Skyrocketing Today

EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line

Zacks

a month ago

EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line

Thomson Reuters StreetEvents

a month ago

Q1 2025 Exelixis Inc Earnings Call

These Stocks Are Moving the Most Today: Nvidia, AMD, Super Micro, UnitedHealth, American Eagle, Exelixis, Grail, and More

Barrons.com

a month ago

These Stocks Are Moving the Most Today: Nvidia, AMD, Super Micro, UnitedHealth, American Eagle, Exelixis, Grail, and More

MT Newswires

a month ago

Morgan Stanley Adjusts Price Target on Exelixis to $47 From $40, Maintains Overweight Rating

Exelixis Inc (EXEL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

GuruFocus.com

a month ago

Exelixis Inc (EXEL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Exelixis [NasdaqGS:EXEL] Sees US$555 Million Revenue With Earnings Up Sharply

Simply Wall St.

a month ago

Exelixis [NasdaqGS:EXEL] Sees US$555 Million Revenue With Earnings Up Sharply

Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks

a month ago

Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Exelixis (EXEL) Surpasses Q1 Earnings and Revenue Estimates

Zacks

a month ago

Exelixis (EXEL) Surpasses Q1 Earnings and Revenue Estimates

MT Newswires

a month ago

Exelixis Q1 Non-GAAP Earnings, Revenue Rise; 2025 Revenue Outlook Lifted -- Shares Up After Hours

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?

Zacks

a month ago

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Zacks

a month ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Is Exelixis, Inc. (EXEL) One of the Best Stocks to Buy According to Jim Simons’ Renaissance Technologies?

Insider Monkey

a month ago

Is Exelixis, Inc. (EXEL) One of the Best Stocks to Buy According to Jim Simons’ Renaissance Technologies?

Ahead of Exelixis (EXEL) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Zacks

a month ago

Ahead of Exelixis (EXEL) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May

Business Wire

a month ago

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May

Argus Research

a month ago

EXEL: Lowering target price to $40.00

Exelixis, Inc. (EXEL): Among the Large-Cap Stocks Insiders and Short Sellers Are Dumping Like Crazy

Insider Monkey

2 months ago

Exelixis, Inc. (EXEL): Among the Large-Cap Stocks Insiders and Short Sellers Are Dumping Like Crazy

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

Zacks

2 months ago

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025

Business Wire

2 months ago

Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Zacks

2 months ago

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

MercadoLibre, The Amazon Of Latin America, Leads Five Stocks Near Buy Points

Investor's Business Daily

2 months ago

MercadoLibre, The Amazon Of Latin America, Leads Five Stocks Near Buy Points

Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum?

Zacks

2 months ago

Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum?

Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline

Zacks

2 months ago

Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline

Here's Why Exelixis (EXEL) is a Strong Value Stock

Zacks

2 months ago

Here's Why Exelixis (EXEL) is a Strong Value Stock

Argus Research

2 months ago

EXEL: What does Argus have to say about EXEL?

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Zacks

2 months ago

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release

High Growth Tech Stocks To Watch In The US April 2025

Simply Wall St.

2 months ago

High Growth Tech Stocks To Watch In The US April 2025

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

Zacks

2 months ago

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

Argus Research

2 months ago

EXEL: Raising target price to $40.00

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?

Zacks

2 months ago

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Zacks

2 months ago

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Argus Research

2 months ago

EXEL: Lowering target price to $37.00

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

Zacks

2 months ago

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

The Smartest Biotech Stocks to Buy With $50

Motley Fool

3 months ago

The Smartest Biotech Stocks to Buy With $50

Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More

Zacks

3 months ago

Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More

Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now?

Insider Monkey

3 months ago

Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now?

Argus Research

3 months ago

EXEL: Lowering target price to $40.00

FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors

Zacks

3 months ago

FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors

Exelixis’ cabozantinib approval ‘certainly positive,’ says Citi

TipRanks

3 months ago

Exelixis’ cabozantinib approval ‘certainly positive,’ says Citi

Exelixis to present positive preclinical data across pipeline portfolio at AACR

TipRanks

3 months ago

Exelixis to present positive preclinical data across pipeline portfolio at AACR

Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?

Zacks

3 months ago

Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?

Exelixis (NasdaqGS:EXEL) Celebrates FDA Approval For Expanded CABOMETYX® Use In Treating NET

Simply Wall St.

3 months ago

Exelixis (NasdaqGS:EXEL) Celebrates FDA Approval For Expanded CABOMETYX® Use In Treating NET

MT Newswires

3 months ago

Exelixis Gets FDA Approval for Drug Treating Patients With Previously Treated Advanced Neuroendocrine Tumors

Here's Why Exelixis (EXEL) is a Strong Growth Stock

Zacks

3 months ago

Here's Why Exelixis (EXEL) is a Strong Growth Stock

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Business Wire

3 months ago

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Argus Research

3 months ago

EXEL: Raising target price to $41.00

Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025

Business Wire

3 months ago

Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025

Biotech Leader Exelixis Eyes Buy Point In Monday's Stock Market Rally

Investor's Business Daily

3 months ago

Biotech Leader Exelixis Eyes Buy Point In Monday's Stock Market Rally

Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound?

Zacks

3 months ago

Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound?

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Zacks

3 months ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Exelixis Growth Continues with Big Money Boosts

FX Empire

3 months ago

Exelixis Growth Continues with Big Money Boosts

Share on Social Networks: